Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of L-Tyrosine Ethylester. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.48 |
| ▸ | ESR1 known ✓ | P03372 | 3/20 | 0.47 |
| ▸ | ESR2 known ✓ | Q92731 | 3/20 | 0.47 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | TPH1 | P17752 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Tyrosine Ethylester SCHEMBL595119 | 1.00 | SLC7A5 (0.59) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL9331146 | 1.00 | SLC7A5 (0.59) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL27732314 | 0.98 | SLC7A5 (0.57) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL9327871 | 0.98 | SLC7A5 (0.61) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL242946 | 0.98 | SLC7A5 (0.61) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL242947 | 0.98 | SLC7A5 (0.61) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL30772131 | 0.95 | SLC7A5 (0.57) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL1532619 | 0.95 | SLC7A5 (0.57) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL27074524 | 0.95 | SLC7A5 (0.57) | SLC7A5TPH1TAAR1SLC6A2HDAC8 | |
| L-Tyrosine Ethylester SCHEMBL3086510 | 0.95 | SLC7A5 (0.57) | SLC7A5TPH1TAAR1SLC6A2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118834232-A | Trifunctional silane coupling agent, preparation method thereof, vulcanized rubber composition and vulcanized rubber | 怡维怡橡胶研究院有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-116783212-A | Compositions and methods for modulating cancer in non-human mammals | 霍夫曼技术有限责任公司 | 2023-09-19 | — | — | CN | claimed |
| CN-115812503-A | Method for reducing Chinese rose flower deformity | 苏州市园艺站 | 2023-03-21 | — | — | CN | claimed |
| US-20220257625-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS | BIODERM, INC. | 2022-08-18 | — | — | US | claimed |
| WO-2021011664-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS | BIODERM, INC. (US) | 2021-01-21 | — | — | WO | claimed |
| EP-3749290-A1 | METHODS FOR DOPAMINE MODULATION IN HUMAN NEUROLOGIC DISEASES | Sackner-Bernstein, Jonathan (US) | 2020-12-16 | — | — | EP | claimed |
| WO-2019147934-A1 | METHODS FOR DOPAMINE MODULATION IN HUMAN NEUROLOGIC DISEASES | SACKNER BERNSTEIN JONATHAN (US) | 2019-08-01 | — | — | WO | claimed |
| CN-109481401-A | Acetylsalicylic acid and its derivative water-base nano emulsion formulation and preparation method thereof and its application | 华欧研创生物科技(深圳)有限公司 | 2019-03-19 | — | — | CN | claimed |
| EP-3429583-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | Tyme, Inc. (US) | 2019-01-23 | — | — | EP | claimed |
| WO-2017160895-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | TYME, INC. (US) | 2017-09-21 | — | — | WO | claimed |
| CN-102827169-B | Novel porphyrin ligand and metal complex, preparation method and application for novel porphyrin ligand | XI AN RUILIAN MODERN ELECTRONIC CHEMICALS CO LTD | 2014-11-05 | — | — | CN | claimed |
| EP-1185260-B1 | ASCORBIC ACID COMPOSITION FOR THE TREATMENT OF AGING OR DAMAGED SKIN | BIODERM INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-6444699-B2 | Method for treatment of aging or damage skin | BIODERM, INC. | 2002-09-03 | — | — | US | claimed |
| EP-1185260-A4 | ASCORBIC ACID COMPOSITION AND METHOD FOR TREATMENT OF AGING OR DAMAGED SKIN | BIODERM INC (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2000056327-A9 | ASCORBIC ACID COMPOSITION AND METHOD FOR TREATMENT OF AGING OR DAMAGED SKIN | BIODERM INC (US) | 2002-03-28 | — | — | WO | claimed |
| US-20020031557-A1 | Ascorbic acid composition and method for treatment of aging or damaged skin | MEISNER LORRAINE FAXON (US) | 2002-03-14 | — | — | US | claimed |
| EP-1185260-A1 | ASCORBIC ACID COMPOSITION AND METHOD FOR TREATMENT OF AGING OR DAMAGED SKIN | BIODERM, INC. (US) | 2002-03-13 | — | — | EP | claimed |
| US-20010041193-A1 | Method for treatment of aging or damaged skin | BIODERM, INC. | 2001-11-15 | — | — | US | claimed |
| US-6217914-B1 | Ascorbic acid composition and method for treatment of aging or damaged skin | BIODERM, INC. | 2001-04-17 | — | — | US | claimed |
| WO-2000056327-A1 | ASCORBIC ACID COMPOSITION AND METHOD FOR TREATMENT OF AGING OR DAMAGED SKIN | BIODERM, INC. (US) | 2000-09-28 | — | — | WO | claimed |